GlassScriptPhysician profile
Jaclyn Collie
NPI 1922509520
$5,899.96
in general payments reported to CMS, 2019-2025
35 companies · $798 in 2025
The $798 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,258 · 2022: $992 · 2023: $1,491 · 2024: $1,361 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.37 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,515.07 | 2021-2025 | |
| Novo Nordisk INC | $708.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $487.62 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $438.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $381.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.28 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $338.58 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $281.34 | 2021-2025 | |
| Amgen INC. | $196.96 | 2021-2025 | Evenity, Prolia |
| Abbott Laboratories | $190.22 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $137.99 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $98.79 | 2022 | |
| Astellas Pharma US INC | $82.05 | 2021-2024 | |
| Lundbeck LLC | $78.13 | 2022-2025 | Vyepti, Rexulti |
| Daiichi Sankyo INC. | $67.43 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.96 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $57.03 | 2023-2024 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $51.55 | 2025 | Fanapt |
| Dynavax Technologies Corporation | $49.91 | 2023-2024 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $48.25 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.53 | 2022-2024 | Caplyta |
| Scilex Pharmaceuticals INC. | $34.32 | 2023 | Ztlido |
| Phathom Pharmaceuticals, INC. | $20.58 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $19.41 | 2023 | |
| Dexcom, INC. | $19.28 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $18.63 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $15.63 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $15.34 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.48 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $13.80 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2022 | |
| Adlon Therapeutics L.P. | $12.64 | 2021 | |
| Eisai INC. | $11.76 | 2021 | |
| Corium, LLC | $9.42 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Collie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.